Introduction
============

*TP53* is a tumor suppressor gene, located on chromosome 17p13.1, with the main function to prevent cancer transformation ([@B9]). P53 is a transcription factor that activates or represses a series of target genes exerting different biological functions ([@B63]; [@B44]). Consequently to a plethora of multiple stress signals, p53 determines cell fate activating apoptosis or maintaining cells at the G1/S regulation point in a reversible cell cycle arrest process; furthermore, it can induce cellular senescence characterized by an irreversible loss of proliferative potential ([@B16]; [@B69]; [@B10]). P53 dysfunction can promote the initiation or progression of different human tumors and confer malignant characteristics, such as altered cellular differentiation, genetic instability, and increased metastatic potential ([@B50]; [@B5]). Generally, *TP53* is inactivated in the majority of human solid tumors by missense mutations and deletions impairing transcriptional function of the protein ([@B53]; [@B51]; [@B26]). Conversely, in hematological malignancies, where p53 mutations are less recurrent, its activity may be likewise compromised by the alterations of MDM2 (**Table [1](#T1){ref-type="table"}**) and ARF ([@B57]; [@B39]), two regulators of p53. MDM2 (mouse double minute-2) binds p53 regulating its stability and cellular localization. This interaction inhibits p53 mediated transcriptional activity and induces p53 proteasomal degradation ([@B19]; [@B73]). ARF (alternative reading frame), instead, is a tumor suppressor encoded by *CDKN2A* gene, that participates to the regulation of p53, by interacting with MDM2. This binding blocks MDM2 shuttling between the nucleus and cytoplasm avoiding p53 degradation ([@B45]; [@B77]).

###### 

MDM2 deregulations in various hematological malignancies.

  Hematological malignancy   MDM2 deregulation               References
  -------------------------- ------------------------------- --------------------------------
  ALL                        overexpression                  [@B82], [@B81]; [@B28]; [@B83]
  AML                        overexpression                  [@B20]; [@B40]; [@B56]
  CLL                        overexpression                  [@B29]; [@B35]
  CML                                                        [@B71]; [@B12]
  HL                         amplification                   [@B42]
  NHL                        overexpression                  [@B54]
  MCL                        amplification, overexpression   [@B64]; [@B30]
  BL                         overexpression                  [@B78]
  BCL                        overexpression                  [@B58]
  DLBCL                      overexpression                  [@B15]
  MM                         overexpression                  [@B67]; [@B41]; [@B68]

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HL, Hodgkin's lymphoma; NHL, non-Hodgkin's lymphoma; MCL, mantle cell lymphoma; BL, Burkitt's lymphoma; BCL, B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; MM, multiple myeloma.

In acute lymphoblastic leukemia (ALL) MDM2 is overexpressed ([@B82], [@B81]; [@B28]) and *CDKN2A* gene is frequently deleted ([@B72]; [@B34]).

In this review, we summarized the current knowledge about p53-MDM2 axis in ALL focusing our attention on a new potential therapeutic agent restoring p53 dependent mechanisms in this hematological disease.

P53 Abnormalities in Acute Lymphoblastic Leukemia
=================================================

*TP53* mutations were considered infrequent in ALL ([@B31]; [@B13]; [@B61]) and were correlated with cytogenetic alterations, like low hypodiploidy, or MYC-rearrangements ([@B32]; [@B66]). Moreover, the disruption of both *TP53* alleles was associated with adverse prognosis ([@B66]). Also the aberrant methylation could contribute to *TP53* gene inactivation; in particular, [@B1] showed that *TP53* promoter resulted methylated in 8 of out 25 ALL patients and its expression was decreased in all the methylated samples. Other literature data found 13 genes, involved in the *TP53* dependent pathway, down-regulated by hypermethylation in a large cohort of ALL patients at diagnosis. Methylation of at least 1 of the 13 genes was observed in 78% of the patients, which significantly correlated with a higher relapse and mortality rate predicting the clinical outcome of patients ([@B76]).

On the other hand, also deregulation of microRNAs was found to be correlated with p53 alteration. In particular, [@B52] focused their attention of *miRNA-126*, a regulator of hematopoietic stem cell quiescence. They found that *mir-126* was highly expressed in human B-ALL and target p53 response genes orchestrating an oncogenic program by down-regulation of p53-dependent pathway. Another microRNA found to have a role as onco-miRNA in ALL was *mir-181a* that down-regulated the expression of tumor suppressor gene *EGR1* ([@B74]).

Finally, p53 was also inactivated by the frequent deletion of *CDNK2A* ([@B72]; [@B34]) and the overexpression of *MDM2* in ALL patients ([@B82], [@B81]; [@B28]).

Current Treatments of All
=========================

B-ALL is a heterogeneous disease on biological and clinical point of view, affecting pediatric, adolescent, adult, and older patients. It prevalently occurs, however, in childhood, in whom the prognosis is more favorable respect to adult patients, reaching a cure rate of 80--90% thanks to multi-agent and intensive combination chemotherapy regimens that have significantly improved the outcome in the pediatric setting ([@B33]; [@B55]), as well as in that of adolescent and younger adults ([@B14]). In other patients, instead, "conventional" treatments remain unsatisfactory ([@B47]; [@B2]; [@B22]), due to pharmacologic resistance ([@B59]; [@B62]) or toxicity events, above all when aggressive "pediatric-like" protocols are applied ([@B17]).

A subset of B-ALL shows *t*(9:22) translocation that generates "Philadelphia" chromosome (Ph) encoding a specific BCR-ABL1 tyrosine kinase fusion protein. This alteration occurs in 3--4% of pediatric ALL and about 25% of adult patients, increasing with age: these patients strongly benefit of the BCR--ABL1 tyrosine kinase inhibitors (TKI) as first-line treatment ([@B46]). However, although TKI monotherapy induces complete remission rates of 90--100% with low toxicity profile even in older patients ([@B75]; [@B25]), the combination of TKI with standard chemotherapy is generally required to obtain higher long-term disease free survival in both adults ([@B24]; [@B23]) and children ([@B6]; [@B7]) with Ph positive ALL.

More recently, new therapies seem to be appealing for treatment of refractory/relapsed patients. They are based on monoclonal antibodies targeting antigens, including CD19, CD20, CD22, and CD52, expressed on leukemic blast cell surface ([@B36]). Rituximab, an anti-CD20 antibody, in combination with conventional chemotherapy, has been shown to improve survival in newly diagnosed CD20+ ALL ([@B49]). Blinatumomab, a T-cell engaging bi-specific single-chain antibody (BiTE) direct to CD19 and CD3, is used as monotherapy in relapsed and refractory ALL, prolonging relapse free survival ([@B4]; [@B43]). Inotuzumab ozogamicin, an anti-CD22 antibody conjugated with a toxin, alone and in combination with chemotherapy, has been promising in relapsed and refractory B ALL ([@B79]). Several newer monoclonal antibodies (ofatumumab, obinutuzumab, epratuzumab, denintuzumab mafodotin and, moxetumomab pasudotox) are currently under investigation as single agents or in combination with a chemotherapeutic back bone ([@B21]).

Other novel clinical approaches are related to immunotherapy by engineering of T-cells, derived from patients or allogeneic donors, with synthetic chimeric antigen receptors (CAR T-cells) that activate T cells enhancing their function ([@B48]; [@B60]).

Pre-Clinical Evidences of MDM2 Inhibition as a Therapeutic Strategy in Acute Lymphoblastic Leukemia
===================================================================================================

To improve the outcome of B-ALL patients, novel therapeutic strategies have been developed, like the reactivation of apoptotic pathway by inhibiting MDM2 protein.

[@B80] demonstrated that Nilotinib, a second generation TKI inhibitor, inhibited MDM2 in both Ph^+^ and Ph^-^ ALL cell lines with high MDM2 expression. This inhibition activated a p53-independent apoptosis by down-regulation of the anti-apoptotic protein XIAP. [@B28] instead showed a cytotoxic activity of Nutlin-3a, a cis-imidazoline small molecules antagonizing Mdm2-p53 binding, in pediatric ALL with p53 wild-type and over-expressing MDM2. Moreover, they also found the positive correlation between MDM2 expression and Nutlin-3A cytotoxicity in ALL. In fact, a major effect of Nutlin was observed in cells over-expressing MDM2 respect to MDM2-negative ALL cells, probably due to the higher induction of p53, p21, Bax, and PUMA ([@B28]).

Moreover, [@B83] performed *in vitro* experiments with Nutlin and the inhibitor of antiapoptotic PI3K/AKT pathway that is frequently activated in different cancer cell types. They demonstrated the synergic effect of these drugs in inducing apoptosis in ALL cells.

Recently, we observed the effects of Nutlin-3a in adult B-ALL confirming the activation of p53-mediated pathway in wild-type p53 ALL cells ([@B70]). Given the clinical significance of BCR-ABL1 mutations in inducing resistance to conventional therapy ([@B65]), we analyzed the efficacy of Nutlin-3a in Ph^+^ ALL resistant patients carrying the T315I BCR-ABL1 mutation. Interestingly, we observed that this drug is able to reduce *in vitro* cell viability in this subtype of resistant ALL suggesting its potential therapeutic application in resistant clinical setting of patients ([@B70]).

Moreover, due to the evidences that ETV6/RUNX1 (E/R), the most common fusion gene in childhood ALL, impaired p53 signaling, [@B37] investigated the effect of Nutlin in E/R ALL cells. They demonstrated that MDM2 was over-expressed in E/R-positive respect to E/R-negative primary B-cell precursor-ALL samples, showing also that E/R transcription factor binds to the MDM2 P2 promoter and consequently up-regulates MDM2 in a direct and p53-independent manner. Nutlin-3 treatment reactivated p53 function in E/R-expressing leukemic cell lines, leading to cell cycle arrest, enhanced apoptosis, and increased expression of p53 direct targets p21, MDM2, and the pro-apoptotic BAX and PUMA ([@B37]).

Furthermore, [@B57] carried out a preclinical study in a specific subset of infant ALL patients carrying the translocation in the mixed-lineage leukemia (MLL) oncogene, associated with a lower survival rate. They demonstrated that RG7112, the analog of Nutlin-3a, induced regression and prolonged progression delay in a panel of patient-derived infant MLL-ALL xenografts, and p53 upregulation, cell cycle arrest and induction of apoptosis.

[@B38] instead tested the efficacy of another inhibitor of MDM2, MK-8242, in *in vitro* and *in vivo* tumor panels and compared this study with their previous evaluation of RG7112 in the same cell line models ([@B11]). For both agents, they demonstrated that the *in vitro* ALL cell line sensitivity correlated with *TP53* mutation status. Moreover, for *in vivo* experiments, the response of the leukemia xenografts was similar between MK-8242 and RG7112; in particular, xenografts from two MLL-rearranged cell lines achieved or maintained complete responses. Other non-MLL ALL xenografts had partial responses to MK-8242.

Interestingly, emerging literature data reported that MDM2 inhibition played a role not only in apoptosis induction but also in autophagy activation in different hematological malignancies, like multiple myeloma ([@B27]) and acute myeloid leukemia (AML; [@B8]).

Collectively, these different studies indicated that MDM2 inhibition could be a new promising target therapy in hematological malignancies.

Use of MDM2 Inhibitors in Combination Setting
=============================================

Since drug resistance to MDM2 inhibitors or current therapeutic agents can be acquired by tumor cells, pharmacological combination could be a successful strategy to improve the treatment outcome and to reduce the side-effects of the drugs. In this regard, different groups evaluated *in vitro* the combinatory effects between Nutlin-3a and conventional drugs used in ALL therapy. [@B37] reported that co-exposure of Nutlin-3a and chemotherapeutic drugs (daunorubicin, asparaginase, vincristine) reduced cell viability and potentiated apoptosis in a childhood ALL cell line, with E/R fusion gene.

In our previous study, we evaluated *in vitro* the co-treatment of Nutlin-3a with TKIs in Ph^+^ cell lines. In particular, the combination between Nutlin-3a and Imatinib, Dasatinib or Nilotinib showed significant effect in reducing cell viability of a Ph+ cell line in comparison with the effect of the single TKI treatment ([@B70]).

Another study by [@B57], showed that combining RG7112 with an induction type regimen (vincristine, dexamethasone, and [L]{.smallcaps}-asparaginase) significantly enhanced objective responses and prolonged leukemia regression *in vivo* MLL-ALL xenografts.

On the light of these pre-clinical evidences, literature data underline that targeting the p53-MDM2 axis in combination with established drugs for the management of ALL warrants further investigations.

MDM2 Inhibitors in Clinical Trials
==================================

As previously described, different preclinical studies demonstrated the *in vitro* and *in vivo* effects of MDM2 inhibitors to kill wild-type p53 tumor cells. Therefore, due to their promising anticancer abilities, these drugs are now translated into clinical trials to better assess their biological effects and toxicities in patients. RG7112 was the first MDM2 inhibitor entered clinical evaluation. Recently, a multicenter phase I trial of RG7112 was conducted in patients with hematological malignancies, including ALL ([@B3]). This study confirmed p53 stabilization and transcriptional activation of p53 target genes after MDM2 antagonist treatment, also demonstrating clinical activity in patients with poor prognosis, relapsed, or refractory. To identify the effective biomarkers of response, in this study were evaluated the p53 status by detection of single nucleotide substitution or deletion in exons 2-11 as well as their splice sites. Moreover, mRNA expression, by quantitative real-time PCR, of 24 direct and indirect p53 target genes and MDM2 transcript was also examined. By analyzing patient data the authors did not find any molecular marker predicting response to RG7112. Since this inhibitor was effective in patients with at least 1 wild-type *TP53* allele, *TP53* mutation status alone did not define pharmacological response. Furthermore, baseline MDM2 expression levels were found positively correlated with clinical response, but also this was not sufficient to define MDM2 as a single predictive marker of sensitivity to treatment. The analysis of p53 target genes showed 10, among 24, p53 target genes significantly modulated but only in p53 wild-type samples. Among those, the most induced genes were *CDKN1A*/p21, a crucial p53-mediator of cell-cycle arrest, and *BBC3*/PUMA, an important mediator of p53 dependent apoptosis ([@B3]).

However, from a clinical point of view, RG7112 showed several disadvantages as the gastrointestinal intolerance due to a high dose required for drug efficacy and variability of exposure at the maximum tolerate dose. To overcome these limitations, recently a new potent MDM2 inhibitor RG7388, also known as Idasanutlin, has been discovered ([@B18]) and actually entered in a phase 1/1b study in relapsed/refractory AML. Recent data about this trial revealed that MDM2 protein expression levels in leukemic blasts and stem cells were associated with Idasanutlin-induced complete remission in AML patients ([@B56]). Moreover, the same trial evaluated Idasanutlin as monotherapy or in combination with cytarabine in relapsed/refractory AML patients ([@B56]). No current data are available on ALL.

Conclusion
==========

P53 pathway is often altered in ALL, in particular due to the overexpression of *MDM2* and deletion of *CDKN2A*, the two main regulator of p53. Thus, targeting of MDM2-p53 axis could represent an attractive cancer therapeutic strategy in ALL. Nodaway, potent and selective MDM2 inhibitor drugs are available, such as Nutlins (**Figure [1](#F1){ref-type="fig"}**). These small molecules not only showed a preclinical evidence to restore p53 pathway, but also had a pharmaceutical properties and entered into clinical trials.

![**Reactivation of p53 pathway via Nutlin-3a in acute lymphoblastic leukemia (ALL).** In response to oncogenic activation, ARF protein interacts with MDM2 sequestering it into the nucleolus. This binding prevents the proteasomal degradation of p53 that activates its target genes promoting several functions like apoptosis, growth arrest, DNA repair, and senescence. In ALL, *9p21* locus deletion and MDM2 overexpression eliminate the tumor surveillance mechanism based on ARF-MDM2 interaction leading to the p53 degradation. Nutlin-3a, a small molecule targeting MDM2, restores p53 pathway, suggesting a promising therapeutic option for ALL.](fphar-07-00491-g001){#F1}

Clinical testing of Nutlin-3a and new agents activating p53 tumor suppressor functions may provide proof of concept for their therapeutic approaches in ALL.
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